Navigation Links
Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
Date:8/3/2011

WAYLAND, Mass., Aug. 3 , 2011) /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The contract totals $2.9 million over 2 years provided that key milestones are achieved. Should Avaxia's program meet its anticipated endpoints at the end of this contract, the company hopes to pursue future opportunities with BARDA.  

Dr. Barbara Fox, Avaxia's CEO, commented, "We are very pleased to receive this contract and are proud to be working on this program related to our country's national defense. With this funding, we will be advancing our oral antibody product through the key efficacy studies needed to support the product's use as a nuclear threat countermeasure. This contract will permit us to complete the pre-clinical pharmacology studies for this potential therapy. We look forward to working with BARDA to develop a novel drug that can effectively protect the gastrointestinal tract from radiation damage.

This award provides Avaxia with a new drug development program that is of significant benefit to the company.  Besides providing the company with additional scientific infrastructure, the research to be conducted on this therapeutic will contribute to and support our innovative technology platform and bolster work being done in the related field of inflammatory bowel disease.  Also, should the project meet its targets, the manufacturing and sales of a radiation mitigation drug will increase the commercial opportunities for the company."

About BARDA:  The Biomedical Advanced Research and Development Authority (BARDA), is part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.  BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, stockpile acquisition, innovation, and manufacturing infrastructure building of the necessary vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health medical emergencies including chemical, biological, radiological, and nuclear threats, and pandemic influenza, and emerging infectious diseases. For additional information, visit www.hhs.gov/aspr.

About Avaxia Biologics, Inc.:  Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, oral mucositis, celiac disease, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Canada Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. China Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
5. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
9. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LONDON , January 19, 2017 Incretin ... Sympathomimetics and Others The global anti-obesity drugs ... the first half of the forecast period and CAGR of 38.7% ... expected to grow at a CAGR of 32.8% from 2016 to ... million in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... Jan. 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... specializing in the treatment of non-melanoma skin cancers ... superficial radiation therapy, today announced that it will ... financial results on Thursday, February 2, 2017 after the ... a conference call with the investment community on Thursday, ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... New Therapeutic Option to Address Motor Symptoms and ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Fabrizio Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it will be co-hosting ... in innovative excipients and drug delivery solutions to health industries worldwide. The one ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... who administered fillers that resulted in severe facial disfiguration. After four frightening years ... by doctors at UCLA Medical Center, who removed the substances in a partial ...
(Date:1/19/2017)... ... 2017 , ... Ultimate Medical Academy (UMA) is preparing to ... making a difference in the lives of the next generation of healthcare professionals. ... educational institution, has more than 30,000 alumni and employs more than 2,000 professionals. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family owned and ... is inaugurating a charity event to honor Chad Phillip Dermyer, a local police trooper ... Chad Phillip Dermyer and his fellow officers were conducting routine stops of suspects when ...
(Date:1/19/2017)... San Mateo, CA (PRWEB) , ... January 19, ... ... now being taken in the 2017 Spring Create Real Impact contest from Impact ... through March 17 at http://www.createrealimpact.com . , Educational grants totaling $15,000 ...
Breaking Medicine News(10 mins):